SIP
SGMT icon

Stoneridge Investment Partners’s Sagimet Biosciences SGMT Stock Holding History

Stoneridge Investment Partners’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,836
Closed -$68K – 147
2025
Q1 		$68K Hold
20,836
– – 0.06% 103
2024
Q4 		$94K Buy
20,836
+3,780
+22% +$19.1K 0.03% 120
2024
Q3 		$47K Hold
17,056
– – 0.02% 114
2024
Q2 		$58K Buy
17,056
+1,321
+8% +$6.06K 0.02% 120
2024
Q1 		$85K Buy
+15,735
New +$113K 0.03% 111

Other funds holding SGMT

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return

Stoneridge Investment Partners's SGMT Position: Q2 2025 in Review

Stoneridge Investment Partners sold out of Sagimet Biosciences (SGMT) in Q2 2025, closing a stake of 20,836 shares — an estimated $68K sold.

Stoneridge Investment Partners first reported a position in SGMT in Q1 2024 and held it in 5 quarters. The position peaked at $94K in Q4 2024. 67 funds tracked by Wall St. Rank hold SGMT as of Q2 2025.

  • Stoneridge Investment Partners reported no remaining Sagimet Biosciences position as of Q2 2025 after selling out during the quarter.
  • Stoneridge Investment Partners sold 20,836 Sagimet Biosciences shares in Q2 2025, an estimated $68K.
  • Stoneridge Investment Partners first reported a position in Sagimet Biosciences in Q1 2024 and held it in 5 quarters.
  • Stoneridge Investment Partners's Sagimet Biosciences position peaked at $94K in Q4 2024.
  • 67 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2025.

Based on Stoneridge Investment Partners's 13F filing for Q2 2025, filed 11 Aug 2025.